Description

TENVIR AF TAB (1X30)

Indications

TENVIR AF TAB is primarily indicated for the treatment and management of chronic hepatitis B virus (HBV) infection in adults and pediatric patients aged 12 years and older. It is also used as part of a comprehensive treatment regimen for HIV-1 infection in combination with other antiretroviral agents. The medication is effective in reducing viral load, improving liver function, and preventing the progression of liver disease associated with chronic HBV infection.

Mechanism of Action

TENVIR AF TAB contains tenofovir alafenamide, a prodrug of tenofovir, which is an antiviral medication belonging to the class of nucleotide reverse transcriptase inhibitors (NRTIs). The active form of tenofovir inhibits the reverse transcriptase enzyme, which is crucial for the replication of both HBV and HIV-1. By incorporating itself into the viral DNA chain, tenofovir prevents further elongation, thereby halting viral replication. This mechanism helps in reducing the viral load in the body, leading to improved clinical outcomes for patients.

Pharmacological Properties

The pharmacokinetics of TENVIR AF TAB indicate that after oral administration, tenofovir alafenamide is rapidly absorbed and converted to its active form, tenofovir diphosphate. This active metabolite has a high intracellular concentration, which is essential for its antiviral activity. The drug exhibits a long half-life, allowing for once-daily dosing, which enhances patient adherence to the treatment regimen. TENVIR AF TAB is primarily eliminated through renal excretion, necessitating caution in patients with compromised renal function.

Contraindications

TENVIR AF TAB is contraindicated in patients with a known hypersensitivity to tenofovir alafenamide or any of the excipients in the formulation. Additionally, it should not be used in patients with severe renal impairment (eGFR < 15 mL/min) or those requiring dialysis, as the safety and efficacy of the drug in these populations have not been established. Caution is also advised in patients with a history of significant renal disease or those who are concurrently taking nephrotoxic medications.

Side Effects

Common side effects associated with TENVIR AF TAB include nausea, diarrhea, headache, fatigue, and abdominal pain. These side effects are generally mild to moderate in severity and often resolve with continued use of the medication. However, serious adverse reactions can occur, including renal impairment, lactic acidosis, and hepatotoxicity. Patients should be monitored regularly for signs of these serious side effects, especially during the initial stages of treatment.

Dosage and Administration

The recommended dosage of TENVIR AF TAB for adults and pediatric patients (aged 12 years and older) is one tablet taken orally once daily, with or without food. It is crucial for patients to adhere to the prescribed dosage and to not discontinue the medication abruptly without consulting their healthcare provider, as this may lead to a rebound increase in viral load. For patients with renal impairment, dosage adjustments may be necessary based on renal function, and regular monitoring of renal parameters is advised.

Interactions

TENVIR AF TAB may interact with other medications, particularly those that are nephrotoxic or that affect renal function. Concomitant use of other antiretroviral agents, such as atazanavir or ritonavir, may also influence the pharmacokinetics of tenofovir alafenamide. It is essential for healthcare providers to review a patient’s complete medication list to identify potential drug-drug interactions and to adjust treatment regimens accordingly. Patients should be advised to inform their healthcare provider of all medications, supplements, and herbal products they are taking.

Precautions

Prior to initiating treatment with TENVIR AF TAB, a thorough assessment of renal function is recommended. Regular monitoring of renal parameters, including serum creatinine and phosphate levels, should be performed throughout the treatment course. Patients with a history of hepatitis B should be closely monitored for signs of liver function deterioration upon discontinuation of therapy. Additionally, patients should be educated about the importance of adherence to the prescribed treatment regimen and the potential risks associated with missed doses.

Clinical Studies

Clinical studies have demonstrated the efficacy and safety of TENVIR AF TAB in the management of chronic hepatitis B and HIV-1 infections. In a randomized controlled trial, patients receiving tenofovir alafenamide showed a significant reduction in HBV DNA levels compared to those receiving a placebo. Furthermore, the safety profile of TENVIR AF TAB was favorable, with a lower incidence of renal toxicity compared to older formulations of tenofovir. These findings support the use of TENVIR AF TAB as a first-line treatment option for eligible patients.

Conclusion

TENVIR AF TAB (1X30) is a valuable therapeutic option for the treatment of chronic hepatitis B and HIV-1 infections. With its favorable pharmacological properties, once-daily dosing, and a manageable side effect profile, it offers an effective solution for patients requiring antiviral therapy. As with any medication, careful consideration of contraindications, potential side effects, and drug interactions is essential to ensure optimal patient outcomes. Regular monitoring and patient education play critical roles in the successful management of therapy with TENVIR AF TAB.